Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Adagrasib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Adagrasib as a study intervention. Browse Adagrasib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
37
Shown on this page
12
Current sort
Recently updated
Therapy scope
Adagrasib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Adagrasib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 25–36 of 37 matching trials for Adagrasib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Withdrawn Phase 2 Interventional

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

NCT05472623
View directory record Official record
Conditions
Resectable Non-Small Cell Lung Cancer
Interventions
Adagrasib, Adagrasib/Nivolumab
Drug · Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

NCT05162443
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
Interventions
adagrasib (MRTX849)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
San Francisco, California • Santa Rosa, California • Hartford, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Withdrawn Phase 1 Interventional

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

NCT05634525
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
MRTX849
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986466, Adagrasib, Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets

NCT06801418
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

NCT04418661
View directory record Official record
Conditions
Metastatic Neoplasm
Interventions
Vociprotafib, Pembrolizumab, Adagrasib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Orange, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Terminated Phase 1 Interventional

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NCT05840510
View directory record Official record
Conditions
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
Adagrasib, nab-Sirolimus
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Completed Phase 1 Interventional

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

NCT04330664
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
MRTX849, TNO155
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Completed Phase 1 Interventional

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

NCT05178888
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
MRTX849, Palbociclib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Orlando, Florida • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 16, 2026, 10:42 PM EDT
Terminated Phase 1 Interventional

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

NCT04975256
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions
MRTX849, BI 1701963
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 16, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

NCT05868356
View directory record Official record
Conditions
Healthy Adults
Interventions
Treatment A, Treatment B
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 16, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

NCT05924152
View directory record Official record
Conditions
Healthy Adults
Interventions
Adagrasib, Eltrombopag + adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 16, 2026, 10:42 PM EDT

About this Adagrasib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Adagrasib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Adagrasib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Adagrasib.